Open AccessCariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives
Author(s) -
Christoph U. Correll,
Koen Demyttenaere,
Andrea Fagiolini,
Göran Hajak,
Stefano Pallanti,
Giorgio Racagni,
Swaran P. Singh
Publication year - 2020
Publication title -
future neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 32
eISSN - 1748-6971
pISSN - 1479-6708
DOI - 10.2217/fnl-2020-0012
Subject(s) - schizophrenia (object oriented programming) , hypoactivity , dopaminergic , psychology , neuroscience , antipsychotic , prepulse inhibition , psychiatry , medicine , dopamine
In schizophrenia, dopaminergic hyperactivity in the mesolimbic regions, or possibly even selectively so in the dorsal striatum, seems to cause the emergence of psychotic symptoms, whereas dopaminergic hypoactivity in cortical regions underlies the negative symptoms and cognitive deficits. Managing the negative symptoms is a major current challenge in the treatment of schizophrenia with a dearth of novel modalities to address this clinical issue. Cariprazine is a novel second-generation antipsychotic that specifically targets the D3 receptor mainly associated to negative symptoms. The review summarizes the main issues regarding negative symptom management and the role of cariprazine treatment.